Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Status:
Terminated
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/1b study of SC-003 as a single agent and in combination with ABBV-181 in
patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug
conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. ABBV-181
is a humanized, recombinant, mAb that binds to cell surface expressed programmed cell death 1
(PD-1).